Tenet: A Real Soap Opera

The bad news at acute care hospital operator Tenet Healthcare (NYSE: THC  ) keeps getting worse. Today, the company announced that it expects weak results to continue into the fourth quarter. While holding out the hope that 2005 will "improve meaningfully," the company also said that it doesn't expect results to exceed breakeven.

If Wall Street gave awards for soap operas, the story line for Tenet would have to be a finalist. Back in August 2003, the company reported it was being investigated by the Florida Medicaid Fraud Control Unit -- while at the same time saying it paid $54 million to settle with the Feds and California over a series of unnecessary heart procedures.

Fast-forward to today, and the company says, "For volumes to recover, however, we need to substantially resolve our open litigation and investigation matters." With red flags like that, how confident can an investor be about breakeven in the semi-near future?

What really makes this story line worse are planned noncash charges that "could exceed $1 billion." Real money (regardless of whether it was stock or cash) got those "assets" there. Ah, but with the accountant's click of a mouse, they will disappear.

Tenet assures investors that it expects there will be roughly $1.3 billion in cash at the end of 2004 -- the same level as at the end of September. Good news? Maybe, but it's perhaps more than compensated for by Tenet's $4.5 billion in total debt.

Back in January 2003, Tenet expected to earn $1.80 to $2.20 in fiscal 2004. Fat chance. The line for the fourth quarter now is that results will be "below comparable third-quarter results." In plain English, net income will be negative -- and there will be the aforementioned ugly write-off too.

With today's news, the stock is down almost 10% to under $11 -- an award-winning rock impersonation considering it has dropped from $52.07 in June 2002.

The population is aging, and hospitals are well-positioned for growth. For now, investors would be wise to look at giant HCA (NYSE: HCA  ) or smaller Triad Hospitals (NYSE: TRI  ) and wait for Tenet to complete its ongoing soap opera.

For related Fool analysis, click to:

The Motley Fool is investors talking to investors. Discuss Tenet, HCA, and thousands of stocks -- or just investing in general -- on The Motley Fool discussion boards.

Fool contributor W.D. Crotty does not own stock in any of the companies mentioned.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 504306, ~/Articles/ArticleHandler.aspx, 10/28/2016 4:17:17 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,162.01 -7.67 -0.04%
S&P 500 2,126.41 -6.63 -0.31%
NASD 5,190.10 -25.87 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/28/2016 3:59 PM
THC $20.24 Down -0.45 -2.17%
Tenet Healthcare CAPS Rating: **
TRI $39.51 Down -0.06 -0.15%
Thomson Reuters CAPS Rating: **